ism1 Antibody

What is ISM1 and why study it with antibodies?

ISM1 (Isthmin 1) is a secreted protein encoded by the ISM1 gene with a canonical length of 464 amino acid residues and a molecular mass of 52.1 kDa in humans. As a member of the Isthmin protein family, it functions primarily as an angiogenesis inhibitor . ISM1 is particularly important in maintaining lung homeostasis via cell-surface GRP78-mediated signaling. Antibodies against ISM1 are essential tools for investigating its expression, localization, and function in normal physiology and disease states, particularly in conditions like COPD where ISM1 dysfunction may play a role .

ISM1 has been found to undergo post-translational modifications, including glycosylation, which can affect its biological activity and detection. The isthmin 1 marker is also useful for characterizing specific neuronal populations, including Gray Matter Chandelier Neurons and Dorsal Excitatory Neurons .

What applications are ISM1 antibodies suitable for?

ISM1 antibodies are commonly used in multiple experimental applications:

Western blot analysis is the most common application for ISM1 antibodies, allowing researchers to detect and quantify ISM1 protein expression across different experimental conditions or disease states . When conducting IHC experiments, researchers should optimize antibody concentration for their specific tissue samples and fixation methods.

How should ISM1 antibodies be stored for optimal performance?

For short-term storage (up to 2 weeks), ISM1 antibodies should be maintained at refrigerated temperatures (2-8°C). For long-term storage, they should be kept at -20°C in small aliquots to prevent repeated freeze-thaw cycles that can significantly compromise antibody activity . Most commercial ISM1 antibodies are supplied in PBS with 0.09% (W/V) sodium azide as a preservative, which helps maintain stability during storage .

When working with ISM1 antibodies, thaw aliquots completely before use and mix gently to ensure homogeneity. Avoid vortexing as this can cause protein denaturation and antibody aggregation that reduce specificity and sensitivity.

How can I validate the specificity of ISM1 antibodies?

Rigorous validation of ISM1 antibodies is essential for reliable experimental results. Multiple approaches should be employed:

• Positive and negative control samples: Use tissues or cells known to express high levels of ISM1 (e.g., placenta) as positive controls . For negative controls, utilize ISM1 knockout models or cell lines where ISM1 expression has been silenced via CRISPR-Cas9 or siRNA.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application. If the antibody is specific, this should abolish or significantly reduce the signal.

• Orthogonal methods: Confirm antibody specificity by correlating results with mRNA expression data from qPCR or RNA-seq.

• Western blot analysis: Verify that the detected band corresponds to the expected molecular weight of 52.1 kDa for human ISM1, accounting for potential post-translational modifications like glycosylation .

• Cross-species reactivity assessment: If working with non-human models, confirm reactivity with the target species, as ISM1 orthologs exist in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken .

What are the best methodological approaches for studying ISM1's role in lung homeostasis?

Based on recent research, ISM1 plays a critical role in maintaining lung homeostasis by regulating alveolar macrophage (AM) populations. When designing experiments to investigate this function:

• In vivo studies: Compare wild-type and Ism1-/- mouse models to evaluate lung function parameters, inflammation markers, and alveolar macrophage populations. Key readouts should include total lung capacity, forced expiratory volumes, and the FEV100/FVC ratio .

• Alveolar macrophage characterization: Use flow cytometry with appropriate markers (CD45+Siglec-F+CD11c+) to identify residential AMs and assess their morphological heterogeneity and cell-surface GRP78 (csGRP78) expression levels .

• Intratracheal delivery of recombinant ISM1: Administer rISM1 to Ism1-/- mice to assess its therapeutic potential in reducing csGRP78high AM populations and attenuating emphysema progression. Careful dose-response studies are essential to determine optimal concentrations .

• Co-localization studies: Perform dual immunostaining for ISM1 and csGRP78 to investigate their interaction in lung tissue sections, combined with markers for apoptosis (e.g., cleaved caspase-3) to assess the mechanism of AM depletion .

How can I troubleshoot non-specific binding issues with ISM1 antibodies?

Non-specific binding is a common challenge when working with antibodies. For ISM1 antibodies specifically:

• Optimize blocking conditions: Test different blocking reagents (BSA, normal serum, commercial blockers) at various concentrations and incubation times. For IHC applications, 5% normal goat serum in PBS is often effective.

• Adjust antibody dilution: Non-specific binding can occur when antibody concentration is too high. Test a dilution series (e.g., 1:1000, 1:2000, 1:5000 for Western blot) to identify the optimal working concentration .

• Increase washing stringency: Add 0.1-0.3% Tween-20 to wash buffers and increase the number and duration of washing steps to remove weakly bound antibodies.

• Reduce cross-reactivity: Pre-adsorb the antibody with proteins from species that might cause cross-reactivity or include species-specific IgG in the blocking solution.

• Consider epitope masking: If the target epitope (amino acids 435-464 for some commercial antibodies) might be masked by protein interactions or conformational changes, try different antigen retrieval methods for IHC or denaturing conditions for Western blot .

How should I design experiments to investigate ISM1's angiogenesis inhibitory function?

ISM1's role as an angiogenesis inhibitor can be studied through multiple experimental approaches:

• Endothelial cell assays:

  • Tube formation assays using HUVECs treated with recombinant ISM1 at different concentrations

  • Migration and proliferation assays to assess the direct effects of ISM1 on endothelial cell behavior

  • Analyze downstream signaling pathways using phosphorylation-specific antibodies

• Ex vivo models:

  • Aortic ring assays with tissues from wild-type versus Ism1-/- mice

  • Chorioallantoic membrane (CAM) assays with localized application of ISM1 antibodies or recombinant protein

• In vivo models:

  • Matrigel plug assays comparing angiogenesis in wild-type versus Ism1-/- mice

  • Tumor xenograft models to assess ISM1's impact on tumor vascularization

  • Retinal angiogenesis models to visualize vascular development

When designing these experiments, include appropriate positive controls (established angiogenesis inhibitors like endostatin) and negative controls (vehicle or isotype control antibodies).

What are the considerations for using ISM1 antibodies in different model species?

When working with ISM1 across different species, consider the following:

Gene orthologs of ISM1 have been identified in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken species . When selecting antibodies for cross-species studies:

• Epitope conservation: Compare the amino acid sequence of the antibody's target epitope across species. Higher conservation suggests better cross-reactivity.

• Validation in target species: Even if an antibody is advertised as cross-reactive, conduct preliminary validation experiments in your species of interest before proceeding with full studies.

• Species-specific secondary antibodies: Use secondary antibodies specific to the host species of your primary antibody to minimize background.

• Positive controls from target species: Include tissue samples known to express ISM1 in your species of interest as positive controls .

What is the optimal protocol for using ISM1 antibodies in Western blot analysis?

For optimal Western blot results with ISM1 antibodies:

• Sample preparation:

  • For tissues: Homogenize in RIPA buffer with protease inhibitors

  • For cell culture: Lyse cells directly in 1X Laemmli buffer or RIPA buffer

  • Include phosphatase inhibitors if studying signaling pathways

• Gel selection and transfer:

  • Use 10% SDS-PAGE gels for optimal resolution of the 52.1 kDa ISM1 protein

  • Transfer to PVDF membranes (preferred over nitrocellulose for glycoproteins)

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Dilute primary ISM1 antibody 1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 4x with TBST, 5 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody (typically 1:10,000) for 1 hour at room temperature

• Detection:

  • For human placenta tissue lysates at 20 μg per lane, a distinct band at approximately 52 kDa should be visible

  • Use enhanced chemiluminescence (ECL) for detection, with exposure times optimized for signal intensity

How can I optimize immunohistochemistry protocols with ISM1 antibodies?

For effective IHC with ISM1 antibodies:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin following standard protocols

  • Section at 4-5 μm thickness

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Pressure cooker method: 125°C for 3 minutes or 95°C for 20 minutes

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Block non-specific binding with 5% normal serum from the species of secondary antibody

  • Dilute ISM1 primary antibody at 1:50-1:100 in blocking buffer

  • Incubate overnight at 4°C in a humidified chamber

• Detection system:

  • Use biotin-free polymer detection systems for cleaner backgrounds

  • Counterstain with hematoxylin for nuclear visualization

  • Mount with permanent mounting medium

• Controls:

  • Include tissue sections known to express ISM1 as positive controls

  • Include sections with primary antibody omitted as negative controls

How do I interpret conflicting ISM1 antibody data between different experimental methods?

When faced with discrepancies in ISM1 detection between different methods:

• Consider protein conformation: The epitope recognized by the ISM1 antibody (e.g., amino acids 435-464 in C-terminal antibodies) may be differently exposed in native versus denatured conditions . IHC and IP typically detect native proteins, while Western blot detects denatured proteins.

• Evaluate post-translational modifications: ISM1 undergoes glycosylation which may affect antibody binding. Different extraction methods may preserve or disrupt these modifications differently .

• Assess sensitivity thresholds: ELISA typically offers higher sensitivity than Western blot, potentially detecting ISM1 in samples where Western blot results are negative.

• Examine subcellular localization: Since ISM1 is a secreted protein, cell fractionation experiments can help determine whether discrepancies reflect differences in detecting intracellular versus secreted forms .

• Validate with orthogonal approaches: Complement antibody-based detection with mass spectrometry or mRNA quantification to resolve discrepancies.

How can ISM1 antibodies be used to investigate COPD pathogenesis?

ISM1 antibodies are valuable tools for studying COPD mechanisms based on recent findings about ISM1's role in lung homeostasis:

• Quantitative analysis of ISM1 expression: Use Western blot and ELISA with ISM1 antibodies to compare ISM1 levels in BALF and lung tissue from healthy subjects versus COPD patients .

• Localization studies: Employ immunohistochemistry to map ISM1 distribution in healthy and diseased lung tissues, particularly in relation to alveolar macrophage populations.

• Cell-surface GRP78 co-localization: Perform dual immunofluorescence staining for ISM1 and csGRP78 to identify potential therapeutic targets among alveolar macrophage subpopulations .

• Therapeutic monitoring: In pre-clinical models, use ISM1 antibodies to track the effects of recombinant ISM1 therapy on lung inflammation and emphysema progression, monitoring changes in alveolar macrophage populations .

• Biomarker development: Explore the potential of ISM1 as a biomarker for COPD progression or treatment response using antibody-based detection methods in patient samples.

Key measurements should include functional parameters associated with COPD, such as total lung capacities, volume compartments, pressure-volume measurements, and forced expiratory volumes, particularly the FEV100/FVC ratio, which is equivalent to the FEV1/FVC index used for COPD diagnosis in humans .